The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.

Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

Natural pain relief and muscle recovery compositions having a wide variety of topical applications are provided. In certain embodiments, the pain relief composition includes moringa leaf, moringa oil, a gamma linolenic acid (GLA) source, and a capsaicin source.

Natural pain relief and muscle recovery compositions having a wide variety of topical applications are provided. In certain embodiments, the pain relief composition includes moringa leaf, moringa oil, a gamma linolenic acid (GLA) source, and a capsaicin source.

Natural pain relief and muscle recovery compositions having a wide variety of topical applications are provided. In certain embodiments, the pain relief composition includes moringa leaf, moringa oil, a gamma linolenic acid (GLA) source, and a capsaicin source.

The present invention is a nutraceutical, and method of administering it, to create both a rapid increase in free and total testosterone in the bloodstream as well as modulation of sleep cycles to a PSQI score of 5 or lower, including the key ingredients of 1 mg zinc (chelated or zinc citrate); 1125 mg L-Citrulline Malate (2:1); 400 mg Tesnor (Pomegranate peel and cocoa bean extracts); 150 mg of elevATP, an adenosine triphosphate (ATP) stimulating composition containing peat extract and apple fruit extract; 100-150 mg Tongkat Ali (Eurycoma longifolia) root extract, and 10 mg boron as boron glycinate, together with one or more excipients. The combination of these ingredients, together with optional Vitamin B6, Vitamin B12, and Vitamin D, and optional 25 mg of S7 (green coffee extract (bean), green tea extract (leaf), turmeric extract (rhizome), sour cherry (fruit), blueberry (fruit), broccoli (flower), and kale (leaf)) gives new and unexpectedly improved results over any of the constituents administered alone or in any other combination.